Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends
The global idiopathic pulmonary fibrosis treatment market size is expected treach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 t2030, according ta new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated tboost the growth.
Rise in the initiatives undertaken by manufacturers tdevelop products with novel mechanisms is anticipated tfuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected tbe initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).
An aging population can be expected thave far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated tdrive the market growth during the forecast period.
The dramatic increase in cigarette smoking population is one of the major drivers likely thave a positive impact on market growth. According tthe U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected tlead tthe incidence of IPF.
Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights
Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends
The global idiopathic pulmonary fibrosis treatment market size is expected treach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 t2030, according ta new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated tboost the growth.
Rise in the initiatives undertaken by manufacturers tdevelop products with novel mechanisms is anticipated tfuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected tbe initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).
An aging population can be expected thave far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated tdrive the market growth during the forecast period.
The dramatic increase in cigarette smoking population is one of the major drivers likely thave a positive impact on market growth. According tthe U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected tlead tthe incidence of IPF.
Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights
- Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.
- Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared tinjectable therapies.
- Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.
- U.S. led in 2024 due thigh market penetration and high awareness pertaining tIPF
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: DRUG CLASS BUSINESS ANALYSIS
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Pirfenidone
4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
4.5. Nintedanib
4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
4.6. Interferon Gammato1b
4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Oral
5.4.1. Oral Market, 2018 - 2030 (USD Million)
5.5. Injectable
5.5.1. Injectable Market, 2018 - 2030 (USD Million)
CHAPTER 6. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, ROUTE OF ADMINISTRATION, AND DISTRIBUTION CHANNEL
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. F. Hoffmann-La Roche Ltd
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Boehringer Ingelheim International GmbH
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Bristol-Myers Squibb Company
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Medicinova, Inc
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Merck & Co., Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Galapagos NV
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Novartis AG
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Fibrogen, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: DRUG CLASS BUSINESS ANALYSIS
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Pirfenidone
4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
4.5. Nintedanib
4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
4.6. Interferon Gammato1b
4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Oral
5.4.1. Oral Market, 2018 - 2030 (USD Million)
5.5. Injectable
5.5.1. Injectable Market, 2018 - 2030 (USD Million)
CHAPTER 6. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, ROUTE OF ADMINISTRATION, AND DISTRIBUTION CHANNEL
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. F. Hoffmann-La Roche Ltd
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Boehringer Ingelheim International GmbH
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Bristol-Myers Squibb Company
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Medicinova, Inc
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Merck & Co., Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Galapagos NV
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Novartis AG
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Fibrogen, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
